Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

2016294 citationsJournal Articlegold Open Access

Authors

Rik Vandenberghe · KU Leuven

Juha O. Rinne · Turku PET Centre

Merçé Boada · Fundació ACE

Sadao Katayama · Hiroshima University

Philip Scheltens · Amsterdam UMC Location VUmc

Bruno Vellas · Médipole Garonne

Michael Tuchman · Palm Beach Neurological Center

Abstract

Noncarriers (3000) ClinicalTrials.gov identifier NCT00667810 ; registered 24 Apr 2008. Carriers (3001) ClinicalTrials.gov identifier NCT00676143 ; registered 2 May 2008.

Topics & Keywords

Alzheimer's disease research and treatments S100 Proteins and Annexins Dementia and Cognitive Impairment Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Alzheimer s Research & Therapy

Volume 8, Issue 1, pp. 18-18

DOI: 10.1186/s13195-016-0189-7

Field-Weighted Citation Impact: 17.94